DK3238709T3 - Forbedrede parenterale formuleringer af lipofile farmaceutiske midler og fremgangsmåder til fremstilling og anvendelse af samme - Google Patents
Forbedrede parenterale formuleringer af lipofile farmaceutiske midler og fremgangsmåder til fremstilling og anvendelse af samme Download PDFInfo
- Publication number
- DK3238709T3 DK3238709T3 DK17175794.1T DK17175794T DK3238709T3 DK 3238709 T3 DK3238709 T3 DK 3238709T3 DK 17175794 T DK17175794 T DK 17175794T DK 3238709 T3 DK3238709 T3 DK 3238709T3
- Authority
- DK
- Denmark
- Prior art keywords
- lipofile
- pharmaceuticals
- preparation
- methods
- same
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161480259P | 2011-04-28 | 2011-04-28 | |
| EP12719541.0A EP2701684B1 (en) | 2011-04-28 | 2012-04-20 | Improved parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3238709T3 true DK3238709T3 (da) | 2020-09-28 |
Family
ID=46045121
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17175794.1T DK3238709T3 (da) | 2011-04-28 | 2012-04-20 | Forbedrede parenterale formuleringer af lipofile farmaceutiske midler og fremgangsmåder til fremstilling og anvendelse af samme |
| DK12719541.0T DK2701684T3 (da) | 2011-04-28 | 2012-04-20 | Forbedrede parenterale formuleringer af lipofile farmaceutiske midler og fremgangsmåder til fremstilling og anvendelse af disse |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK12719541.0T DK2701684T3 (da) | 2011-04-28 | 2012-04-20 | Forbedrede parenterale formuleringer af lipofile farmaceutiske midler og fremgangsmåder til fremstilling og anvendelse af disse |
Country Status (16)
| Country | Link |
|---|---|
| US (5) | US9364433B2 (da) |
| EP (2) | EP2701684B1 (da) |
| JP (2) | JP6080312B2 (da) |
| CN (2) | CN107970209B (da) |
| AR (1) | AR086115A1 (da) |
| AU (1) | AU2012250050B2 (da) |
| CA (1) | CA2834262C (da) |
| DK (2) | DK3238709T3 (da) |
| ES (2) | ES2822350T3 (da) |
| HK (2) | HK1245665A1 (da) |
| HU (2) | HUE051400T2 (da) |
| IL (1) | IL229067B (da) |
| MX (1) | MX360638B (da) |
| PL (2) | PL3238709T3 (da) |
| TW (1) | TWI626059B (da) |
| WO (1) | WO2012148799A1 (da) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL152486A0 (en) | 2002-10-25 | 2003-05-29 | Meir Eini | Alcohol-free cosmetic and pharmaceutical foam carrier |
| US8636982B2 (en) | 2007-08-07 | 2014-01-28 | Foamix Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
| US20100233270A1 (en) | 2009-01-08 | 2010-09-16 | Northwestern University | Delivery of Oligonucleotide-Functionalized Nanoparticles |
| WO2011013009A2 (en) | 2009-07-29 | 2011-02-03 | Foamix Ltd. | Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses |
| EP2651450B1 (en) * | 2010-12-16 | 2015-12-16 | Borje S. Andersson | Azole pharmaceutical formulations for parenteral administration and methods for preparing and using the same as treatment of diseases sensitive to azole compounds |
| US9364433B2 (en) * | 2011-04-28 | 2016-06-14 | Borje S. Andersson | Parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same |
| US20140178479A1 (en) * | 2011-08-12 | 2014-06-26 | Perosphere, Inc. | Concentrated Felbamate Formulations for Parenteral Administration |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| JP6285866B2 (ja) | 2011-11-23 | 2018-02-28 | セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． | 天然複合ホルモン補充製剤および療法 |
| GR20120100242A (el) * | 2012-05-04 | 2014-01-02 | Micrel Ιατρικα Μηχανηματα Α.Ε., | Αντλια και προγεμισμενος ασκος/σετ αναλγησιας |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| CN105636583B (zh) * | 2013-09-13 | 2019-08-20 | 板井昭子 | 水溶液制剂及其制造方法 |
| JP6527516B2 (ja) | 2013-12-03 | 2019-06-05 | ノースウェスタン ユニバーシティ | リポソーム粒子、前述のものを作製する方法及びその使用 |
| AU2015264003A1 (en) | 2014-05-22 | 2016-11-17 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US11696883B2 (en) | 2014-05-23 | 2023-07-11 | Triple Hair Inc. | Compositions for reducing hair loss and/or increasing hair regrowth |
| EP3062797B1 (en) | 2014-05-23 | 2019-08-28 | Triple Hair Inc. | Compositions for reducing hair loss and/or increasing hair regrowth |
| EP3508198A1 (en) | 2014-06-04 | 2019-07-10 | Exicure, Inc. | Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications |
| CN105394045B (zh) * | 2014-09-04 | 2020-02-14 | 中国科学院上海巴斯德研究所 | 一种肠道病毒的小分子化合物抑制剂及其应用 |
| US11266621B1 (en) | 2014-10-02 | 2022-03-08 | Exela Sterile Medicines Llc | Methocarbamol composition and related methods |
| WO2016059590A1 (en) * | 2014-10-16 | 2016-04-21 | Piramal Enterprises Limited | Stable injectable composition of small molecule drugs and process for its preparation |
| TWI516520B (zh) | 2014-10-31 | 2016-01-11 | 財團法人工業技術研究院 | 波長轉換聚合物、其製法及包含其之波長轉換裝置 |
| CA2958794C (en) | 2015-07-08 | 2018-10-23 | Triple Hair Inc. | Composition comprising resveratrol and melatonin for reducing hair loss and/or increasing hair regrowth |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| US20170239250A1 (en) | 2016-02-19 | 2017-08-24 | Eagle Pharmaceuticals, Inc. | Pemetrexed formulations |
| BR112018070199A2 (pt) | 2016-04-01 | 2019-01-29 | Therapeuticsmd Inc | composição farmacêutica de hormônio esteroide |
| US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
| CN105837556B (zh) * | 2016-04-11 | 2018-10-26 | 上海工程技术大学 | 一种来那度胺与烟酰胺共晶的制备方法 |
| EP3490552B1 (en) * | 2016-07-26 | 2022-11-23 | University of Southern California | Selective bromodomain inhibition of fungal bdf1 |
| IL265100B2 (en) | 2016-08-31 | 2023-11-01 | Taro Pharma Ind | Topical formulations of phenoldopam for the treatment of skin problems |
| CA2978573A1 (en) | 2016-09-08 | 2018-03-08 | Foamix Pharmaceuticals Ltd. | Compositions and methods for treating rosacea and acne |
| CN106841100A (zh) * | 2016-12-28 | 2017-06-13 | 北京医药集团有限责任公司 | 一种基于近红外光谱技术的小规格口服固体制剂中活性药物成分快速测定方法 |
| US11905525B2 (en) * | 2017-04-05 | 2024-02-20 | Modernatx, Inc. | Reduction of elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins |
| US10463638B2 (en) * | 2017-04-12 | 2019-11-05 | Synergistic Therapeutics, Llc | Therapeutic neuropathic pain lotion |
| US11786607B2 (en) | 2017-06-15 | 2023-10-17 | Modernatx, Inc. | RNA formulations |
| US11744801B2 (en) | 2017-08-31 | 2023-09-05 | Modernatx, Inc. | Methods of making lipid nanoparticles |
| US20210369669A1 (en) * | 2018-10-31 | 2021-12-02 | Systamedic Inc. | Autophagy activators and inhibitors of ferroptosis for preventing acute renal failure and neurotoxcity induced by certain antibiotics |
| CN109627148B (zh) * | 2018-11-28 | 2021-09-03 | 中国农业科学院麻类研究所 | 一种大麻二酚的制备方法、制得的大麻二酚及其用途 |
| CN116966129A (zh) | 2019-03-08 | 2023-10-31 | 塔罗制药工业有限公司 | 稳定的局部用非诺多泮组合物 |
| IL293429A (en) * | 2019-12-04 | 2022-07-01 | RESQ Pharmaceuticals LLC | Methods and preparations for the treatment of edema resistant to oral diuretics |
| US11116737B1 (en) | 2020-04-10 | 2021-09-14 | University Of Georgia Research Foundation, Inc. | Methods of using probenecid for treatment of coronavirus infections |
| CN112697945A (zh) * | 2020-12-18 | 2021-04-23 | 卓和药业集团有限公司 | 泊沙康唑肠溶片含量的分析方法 |
| CN113274379B (zh) * | 2021-05-25 | 2023-04-25 | 湖北工业大学 | Bephenium Hydroxynaphthoate在制备抗EV71药物的应用 |
| CN113768937B (zh) * | 2021-11-15 | 2022-04-08 | 恒翼生物医药科技(上海)有限公司 | 用于降低尿酸水平的化合物 |
| US20230210857A1 (en) * | 2021-12-27 | 2023-07-06 | Enalare Therapeutics Inc. | Respiratory stimulant parenteral formulations |
| CN115721607B (zh) * | 2022-11-19 | 2023-07-21 | 华夏生生药业(北京)有限公司 | 一种乳酸左氧氟沙星注射液及其制备方法 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS475827Y1 (da) | 1970-04-02 | 1972-02-29 | ||
| JPS475827A (da) * | 1971-08-27 | 1972-03-29 | ||
| AU461715B2 (en) * | 1972-01-21 | 1975-05-19 | American Home Products Corporation | Parenteral benzodiazepine compositions |
| DE3316510A1 (de) | 1983-05-06 | 1984-11-08 | Bayer Ag | Parenterale formulierung von nimodipin, ein verfahren zu ihrer herstellung sowie ihre verwendung bei der bekaempfung von erkrankungen |
| US4912124A (en) | 1984-02-23 | 1990-03-27 | Ortho Pharmaceutical Corporation | Antifungal dermatological solution |
| DE3702105A1 (de) | 1987-01-24 | 1988-08-04 | Bayer Ag | Parenterale loesung |
| JPH01242525A (ja) | 1988-03-25 | 1989-09-27 | Nippon Nohyaku Co Ltd | 抗真菌外用剤 |
| US5430057A (en) | 1993-09-30 | 1995-07-04 | Board Of Regents, The University Of Texas System | Parenteral busulfan for treatment of malignant disease |
| US5869474A (en) * | 1997-05-16 | 1999-02-09 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Low dosage treatment for cocaine craving and withdrawal |
| US7030155B2 (en) * | 1998-06-05 | 2006-04-18 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
| US7179475B1 (en) | 1998-12-04 | 2007-02-20 | Johnson & Johnson Consumer Companies, Inc. | Anhydrous topical skin preparations |
| US6383471B1 (en) * | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
| AU5273200A (en) * | 1999-05-24 | 2000-12-12 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
| ES2241663T3 (es) * | 1999-09-21 | 2005-11-01 | Skyepharma Canada Inc. | Composiciones particuladas modificadas superficialmente de substancias biologicamente activas. |
| US6720001B2 (en) * | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
| GB2365770B (en) | 2000-08-18 | 2002-07-31 | Diomed Dev Ltd | Antifungal ketoconazole composition for topical use |
| US20030072807A1 (en) | 2000-12-22 | 2003-04-17 | Wong Joseph Chung-Tak | Solid particulate antifungal compositions for pharmaceutical use |
| US20050048126A1 (en) | 2000-12-22 | 2005-03-03 | Barrett Rabinow | Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug |
| JP2002322056A (ja) | 2001-04-27 | 2002-11-08 | Nippon Kayaku Co Ltd | トリアゾール誘導体の溶液製剤 |
| US6878693B2 (en) | 2001-09-28 | 2005-04-12 | Solubest Ltd. | Hydrophilic complexes of lipophilic materials and an apparatus and method for their production |
| US20050191359A1 (en) * | 2001-09-28 | 2005-09-01 | Solubest Ltd. | Water soluble nanoparticles and method for their production |
| US6991800B2 (en) | 2002-06-13 | 2006-01-31 | Vicuron Pharmaceuticals Inc. | Antifungal parenteral products |
| WO2004014431A1 (en) | 2002-08-12 | 2004-02-19 | Ranbaxy Laboratories Limited | A parenteral dosage form of selective cox-2 inhibitors |
| ZA200409537B (en) | 2003-01-31 | 2006-10-25 | Yamanouchi Pharma Co Ltd | Stable solid medicinal composition for oral administration |
| US9259390B2 (en) * | 2003-08-13 | 2016-02-16 | The University Of Houston System | Parenteral and oral formulations of benzimidazoles |
| GB0412866D0 (en) | 2004-06-09 | 2004-07-14 | Novartis Ag | Organic compounds |
| FR2872703B1 (fr) | 2004-07-07 | 2006-10-06 | Ethypharm Sa | Nanoparticules polymeriques composites |
| CA2581126A1 (en) | 2004-09-24 | 2006-04-06 | Rfe Pharma Llc | Carboxy-amido-triazoles for the localized treatment of ocular diseases |
| EP1863481A1 (en) | 2005-03-31 | 2007-12-12 | Brystol-Myers Squibb Company | Methods for administering ixabepilone |
| EP1895843A4 (en) | 2005-06-27 | 2010-06-02 | Stiefel Laboratories | MICOGEL TOPICAL FORMULAS |
| ITMI20051826A1 (it) | 2005-09-29 | 2007-03-30 | Novachem S A | Kit per la somministrazione parenterale di medicamenti |
| WO2007047253A2 (en) | 2005-10-11 | 2007-04-26 | Eastman Chemical Company | Pharmaceutical formulations of cyclodextrins and antifungal azole compounds |
| US20100166872A1 (en) | 2005-10-21 | 2010-07-01 | Amarjit Singh | Novel improved compositions for cancer therapy |
| JP5403585B2 (ja) * | 2006-01-23 | 2014-01-29 | イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブライ ユニバーシティー オブ エルサレム | 活性薬剤用のデリバリーシステム |
| US20070249546A1 (en) * | 2006-04-22 | 2007-10-25 | Sawaya Assad S | Ophthalmic and related aqueous solutions containing antifungal agents, uses therefor and methods for preparing them |
| US20100160442A1 (en) | 2006-07-18 | 2010-06-24 | Ossovskaya Valeria S | Formulations for cancer treatment |
| WO2008152444A2 (en) | 2006-11-29 | 2008-12-18 | Foamix Ltd. | Foamable waterless compositions with modulating agents |
| US20100204293A1 (en) | 2007-09-05 | 2010-08-12 | Pola Pharma Inc. | Pharmaceutical composition |
| ES2731881T3 (es) * | 2007-09-25 | 2019-11-19 | Formulex Pharma Innovations Ltd | Composiciones que comprenden compuestos activos lipófilos y método para su preparación |
| US20090253712A1 (en) | 2008-04-03 | 2009-10-08 | Semmelweis Egyetem | Aqueous solvent system for solubilization of azole compounds |
| US20090286799A1 (en) | 2008-05-16 | 2009-11-19 | Zhi-Gang Jiang | Methods for the treatment of brain edema |
| AU2009339445A1 (en) | 2009-02-05 | 2011-08-18 | Targeted Delivery Technologies Limited | Methods of reducing the proliferation and viability of microbial agents |
| WO2010117089A2 (en) | 2009-04-09 | 2010-10-14 | Pola Pharma Inc. | Antimycotic pharmaceutical composition |
| US8252821B2 (en) | 2009-04-14 | 2012-08-28 | Bristol-Myers Squibb Company | Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound |
| US20100280031A1 (en) * | 2009-04-30 | 2010-11-04 | Paul David | Lipid formulation of apoptosis promoter |
| EP2651450B1 (en) * | 2010-12-16 | 2015-12-16 | Borje S. Andersson | Azole pharmaceutical formulations for parenteral administration and methods for preparing and using the same as treatment of diseases sensitive to azole compounds |
| US9364433B2 (en) * | 2011-04-28 | 2016-06-14 | Borje S. Andersson | Parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same |
-
2012
- 2012-04-20 US US13/452,033 patent/US9364433B2/en active Active
- 2012-04-20 CA CA2834262A patent/CA2834262C/en active Active
- 2012-04-20 PL PL17175794T patent/PL3238709T3/pl unknown
- 2012-04-20 ES ES17175794T patent/ES2822350T3/es active Active
- 2012-04-20 AU AU2012250050A patent/AU2012250050B2/en active Active
- 2012-04-20 DK DK17175794.1T patent/DK3238709T3/da active
- 2012-04-20 MX MX2013012579A patent/MX360638B/es active IP Right Grant
- 2012-04-20 HU HUE17175794A patent/HUE051400T2/hu unknown
- 2012-04-20 EP EP12719541.0A patent/EP2701684B1/en active Active
- 2012-04-20 JP JP2014508441A patent/JP6080312B2/ja active Active
- 2012-04-20 CN CN201711217375.3A patent/CN107970209B/zh active Active
- 2012-04-20 PL PL12719541T patent/PL2701684T3/pl unknown
- 2012-04-20 ES ES12719541.0T patent/ES2640572T3/es active Active
- 2012-04-20 HU HUE12719541A patent/HUE034480T2/en unknown
- 2012-04-20 WO PCT/US2012/034361 patent/WO2012148799A1/en active Application Filing
- 2012-04-20 EP EP17175794.1A patent/EP3238709B1/en active Active
- 2012-04-20 DK DK12719541.0T patent/DK2701684T3/da active
- 2012-04-20 CN CN201280032690.8A patent/CN103635179B/zh active Active
- 2012-04-25 TW TW101114722A patent/TWI626059B/zh active
- 2012-04-26 AR ARP120101455A patent/AR086115A1/es not_active Application Discontinuation
-
2013
- 2013-10-24 IL IL229067A patent/IL229067B/en active IP Right Grant
-
2014
- 2014-06-09 HK HK18105413.8A patent/HK1245665A1/zh unknown
-
2016
- 2016-05-13 US US15/154,919 patent/US9724345B2/en active Active
- 2016-10-24 JP JP2016208029A patent/JP2017014293A/ja active Pending
-
2017
- 2017-03-07 US US15/451,748 patent/US10028949B2/en active Active
-
2018
- 2018-06-21 US US16/014,908 patent/US10548890B2/en active Active
- 2018-09-04 HK HK18111305.7A patent/HK1251983A1/zh unknown
-
2020
- 2020-01-17 US US16/746,460 patent/US11045466B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3238709T3 (da) | Forbedrede parenterale formuleringer af lipofile farmaceutiske midler og fremgangsmåder til fremstilling og anvendelse af samme | |
| DK2804587T3 (da) | Formulering og fremgangsmåde til øgning af lægemidlers biotilgængelighed | |
| DK2800565T3 (da) | Carbamatforbindelser og fremgangsmåder til fremstilling og anvendelse af samme | |
| CO7020859A2 (es) | Anticuerpos anti-cd134 (ox40) y usos de los mismos | |
| DK3290415T3 (da) | Opioidreceptorligander og fremgangsmåder til anvendelse og fremstilling af samme | |
| DK2683406T3 (da) | Anti-cd40-antistoffer og anvendelser deraf | |
| DK2914627T3 (da) | Anti-cd40-antistoffer og fremgangsmåder til anvendelse | |
| DK2739293T3 (da) | Fremgangsmåder og sammensætninger til frembringelse af vaccinavirus | |
| CO6821892A2 (es) | Anticuerpos anti-angptl3 y usos de los mismos | |
| DK2718270T3 (da) | Sammensætninger og fremgangsmåder til fremstillingen af pyrimidin- og pyridinforbindelser med btk-hæmmende aktivitet | |
| DK3141548T3 (da) | Fremgangsmåder og mellemprodukter til fremstilling af azaindoler | |
| DK3252160T3 (da) | Systemer, fremgangsmåder og sammensætninger med crispr-cas-bestanddele til sekvensmanipulation | |
| DK3378862T3 (da) | Dihydropyrimidinoisoquinolinoner og farmaceutiske sammensætninger deraf til behandlingen af multipel sklerose | |
| DK3415157T3 (da) | N-acyldipeptidderivater og anvendelser deraf | |
| DK2583586T3 (da) | Indretning til registrering af kollisioner og tilsvarende fremgangsmåde | |
| DK2704703T3 (da) | Transdermale sammensætninger af ibuprofen og fremgangsmåder til anvendelse deraf | |
| DK2489670T3 (da) | Fremgangsmåde til fremstilling af aminosyre-chelatforbindelser, aminosyre-chelatforbindelser og anvendelse af aminosyre-chelatforbindelser | |
| DK2729151T3 (da) | Farmaceutisk sammensætning, fremgangsmåder til behandling og anvendelser deraf | |
| DK3050972T3 (da) | Fremgangsmåder til fremstilling af eicosapentaensyre i thraustochytrider | |
| DK3050883T3 (da) | Fremgangsmåde til fremstilling af diazabicyclooctanderivater og mellemprodukter | |
| DK2616035T3 (da) | Indretning til at hjælpe med at gå med støtte | |
| DK2627656T3 (da) | Fremgangsmåde til fremstilling af dihydropteridinon og intermediater deraf | |
| CO6940426A2 (es) | Formulaciones farmacéuticas | |
| DK2600715T3 (da) | Flydende ST-246-formuleringer og fremgangsmåder | |
| DK2896694T3 (da) | Saccharidoxidase og fremgangsmåde til fremstilling deraf og anvendelse deraf |